Sociodemographic, disorder and treatment related characteristics affecting follow-up periods of schizophrenic outpatients;Ayaktan takip edilen şizofreni hastalarinin takip sürelerini etkileyen sosyodemografik, hastalik ve tedaviye ait özellikler

Klinik Psikofarmakoloji Bulteni

Volumn 17, Issue 1, 2007, Pages 15-23

  Sarandöl, Asli ^a   Akkaya, Cengiz ^a   Cangür, Şengül ^a   Mercan, Şener ^a   Pirinççi, Erdal ^a   Kirli, Selçuk ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

Outpatient monitoring; Schizophrenia; Treatment

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT;

ADJUVANT THERAPY; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DEMOGRAPHY; DRUG SUBSTITUTION; FOLLOW UP; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MEDICAL RECORD; OUTPATIENT CARE; PATIENT MONITORING; PROGNOSIS; SCHIZOPHRENIA; SOCIAL ASPECT; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 34047228149     PISSN: 10177833     EISSN: 13029657     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Mason C. Non-attendance at out-patient clinic: a case study. J Adv Nurs 1992; 17: 554-560
2. Nose M, Barbui C, Gray R, Tansella M. Clinical interventions for treatment non-adherence in psychosis: meta-analysis. Br J Psychiatry 2003; 183: 197-206
3. Breen R, Thornhill JT. Noncompliance with medication for psychiatric disorders. Reasons and remedies. CNS Drugs 1998; 9: 457 471
4. Olfson M, Mechanic D, Hansell S, Boyer CA, Walkup J, Weiden PJ. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr Serv 2000; 51: 216-222
5. Norquist GS, Regier DA. The epidemiology of psychiatric disorders and the de facto mental health care system. Annu Rev Med 1996; 47: 473-479
6. Weiden P, Aquila R, Standard J. Atypical antipsychotic drugs and long-term outcome in schizophrenia. J Clin Psychiatry 1996; 57 (Suppl.2): S53-S60
7. Sheitman BB, Lee H, Strauss R, Lieberman JA. The evaluation and treatment of first-episode psychosis. Schizophr Bull 1997; 23: 653-661
8. Yildiz M, Yazici A, Ünal S, Aker T, Özgen G, Ekmekçi H, Duy B, Torun F, Ünsal G, Çoşkun S, Sipahi B, Çakil G, Eryildiz M. Şizofreninin ruhsal-toplumsal tedavisinde sosyal beceri eǧitimi - Belirtilerle baş etme ve ilaç tedavisi yaklaşiminin Türkiye'de çok merkezli bir uygulamasi. Turk Psikiyatri Derg 2002; 13: 41-47
9. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995; 21: 419-429
10. Gilmer TP, Dolder CR, Lacro JP, Folsom DP, Lindamer L, Garcia P, Jeste DV. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004; 161: 692-699
11. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997; 23: 637-651
12. Gorwood P. Meeting everyday challenges: antipsychotic therapy in the real world. Eur Neuropsychopharmacol 2006; 16 (Suppl.3): S156-S162
13. Hofer A, Hummer M, Huber R, Kurz M, Walch T, Fleischhacker WW. Selection bias in clinical trials with antipsychotics. J Clin Psychopharmacol 2000; 20: 699-702
14. Amerikan Psikiyatri Birliǧi. Mental Bozukluklarin Tanisal ve Sayimsal El Kitabi, dördüncü baski (DSM-IV) (Çev. ed.: E Köroǧlu). Hekimler Yayin Birliǧi, Ankara, 1995.
15. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Roseheck RA, Perkins DO, Kefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. NEJM 2005; 353: 1209-1223
16. Haberfellner EM, Rittmannsberger. Weight gain during long-term treatment with olanzapine: a case series. Int Clin Psychopharmacol 2004; 19: 251-253
17. Aqarwal MR, Sharma VK, Kishore Kumar KV, Lowe D. Noncompliance with treatment in patients suffering from schizophrenia: a study to evaluate possible contributing factors. Int J Soc Psychiatry 1998; 44: 92-106
18. Coodin S, Staley D, Cortens B, Desrochers R, McLandress S. Patient factors associated with missed appointments in persons with schizophrenia. Can J Psychiatry 2004; 49: 145-148
19. Kampman O, Laippala P, Vaananen J, Koivisto E, Kiviniemi P, Kilkku N, Lehtinen K. Indicators of medication compliance in first-episode psychosis. Psychiatry Res 2002; 110: 39-48
20. Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand 2002; 106: 286-290
21. Barron WM. Failed appointments: who misses them, why they are missed and what can be done. Prim Care 1980; 7: 563-574
22. Campbell B, Staley D, Matas M. Who misses appointments? An empirical analysis. Can J Psychiatry 1991; 36: 223-225
23. Mooney DK, Johnson RD. Rural mental health appointment adherence: implications for therapy. Community Ment Health J 1992; 28: 135-139
24. Killaspy H, Banerjee S, King M, Llyod M. Prospective controlled study of psychiatric outpatient non-attendance. Characteristics and outcome. Br J Psychiatry 2000; 176: 160-165
25. Chue P. Compliance and convenience: Do physicians and patients see depot medication differently? Acta Neuropsychiatr 2004; 16: 314-318
26. Compton MT. Barriers to initial outpatient treatment engagement following first hospitalization for a first episode of nonaffective psychosis: a descriptive case series. J Psychiatr Pract 2005; 11: 62-69
27. Weiden P, Glazer W. Assesment and treatment. Selection for "revolving door" inpatients with schizophrenia. Psychiatr Q 1997; 68: 377-392
28. Fleischhacker WW, Meise U, Gunther V, Kurz M. Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatr Scand Suppl 1994; 382: 11-15
29. Awad AG, Voruganti LN, Heslegrave RJ, Hogan TP. Assessment of the patient's subjective experiences in acute neuroleptic treatment: implications for compliance and outcome. Int Clin Psychopharmacol 1996; 11 (Suppl.2): S55-S59
30. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002; 63: 1121-1128
31. Jahnssen B, Weinmann S, Berger M, Gaebel W. Validation of polypharmacy process measures in inpatient schizophrenic care. Schizophrenia Bull 2004; 30: 1023-1032
32. Schumacher JE, Makela EH, Griffin HR. Multiple antipsychotic medication prescribing patterns. Ann Pharmacother 2003; 37: 951-955
33. Paton C, Lelliott P, Harrington M, Okocha C, Sensky T, Duffett R. Patterns of antipsychotic and anticholinergic prescribing for hospital inpatients. J Psychopharmacol 2003; 17: 223-229
34. Tapp A, Wood AE, Secrest L, Erdmann J, Cubberley L, Kilzieh N. Combination antipsychotic therapy in clinical practice. Psychiatr Serv 2003; 54: 55-59
35. Ensari H, Ceylan ME, Kilinç E, Kenar J. Türkiye'deki ruh hastaliklari hastanelerindeki psikofarmakolojik tedavilerin kalite yönünden deǧerlendirilmesi. Klinik Psikofarmakoloji Bülteni 2004; 14: 68-78
36. Böke Ö, Sarisoy G, Akbaş S, Aker S, Korkmaz S, Aker AA, Bahçe Z, Çelik C, Şahin AR. Yatan Hastalarda Çoklu Antipsikotik Kullanimi: Geriye Dönük bir Çalişma Klinik Psikofarmakoloji Bülteni 2006; 16: 167-173